Literature DB >> 29205743

Rotational atherectomy and new-generation drug-eluting stent implantation.

Daisuke Hachinohe1, Yoshifumi Kashima1, Daitaro Kanno1, Ken Kobayashi1, Takuro Sugie1, Umihiko Kaneko1, Yutaka Tadano1, Tomohiko Watanabe1, Hidemasa Shitan1, Tsutomu Fujita1.   

Abstract

OBJECTIVES: The aim of this study was to evaluate the clinical outcomes of rotational atherectomy (RA) followed by new-generation drug-eluting stent (DES) implantation in patients with an extensive amount of calcified and fibrotic plaque.
BACKGROUND: RA followed by new-generation DES implantation for complex lesions has not been thoroughly evaluated.
METHODS: A total of 744 consecutive patients (770 lesions) treated with new-generation DES implantation following RA for de novo lesions between January 2013 and November 2015 were retrospectively identified using our institutional database. Clinical outcomes at 12 months were evaluated and the independent predictors of all-cause death and target vessel failure (TVF) were assessed using Cox regression models.
RESULTS: Target lesion revascularization occurred in 22 lesions (2.9%) and TVF occurred in 51 lesions (6.6%). In a multivariate analysis, hemodialysis, non-ST-segment elevation acute coronary syndrome, low ejection fraction, and HbA1c ≧ 7% were associated with 12-month mortality. Hemodialysis and right coronary artery were identified as independent predictors of TVF (hazard ratio (HR) 4.107, 95% confidence interval (CI) 2.194-7.685, P < .001; HR 2.491, 95% CI 1.023-6.062, P = .044, respectively).
CONCLUSIONS: A good debulking with RA followed by new-generation DES implantation is recommended for patients with an excessive amount of calcified and fibrotic plaque, as this will likely improve the clinical outcomes.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  newer-generation drug-eluting stents; percutaneous coronary intervention; rotational atherectomy

Mesh:

Year:  2017        PMID: 29205743     DOI: 10.1002/ccd.27446

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

Review 1.  Rotational atherectomy of calcified coronary lesions: current practice and insights from two randomized trials.

Authors:  Abdelhakim Allali; Mohamed Abdel-Wahab; Karim Elbasha; Nader Mankerious; Hussein Traboulsi; Adnan Kastrati; Mohamed El-Mawardy; Rayyan Hemetsberger; Dmitriy S Sulimov; Franz-Josef Neumann; Ralph Toelg; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2022-04-28       Impact factor: 5.460

Review 2.  Clinical expert consensus document on rotational atherectomy from the Japanese association of cardiovascular intervention and therapeutics.

Authors:  Kenichi Sakakura; Yoshiaki Ito; Yoshisato Shibata; Atsunori Okamura; Yoshifumi Kashima; Shigeru Nakamura; Yuji Hamazaki; Junya Ako; Hiroyoshi Yokoi; Yoshio Kobayashi; Yuji Ikari
Journal:  Cardiovasc Interv Ther       Date:  2020-10-20

3.  Relationship between Metabolic Syndrome and Clinical Outcome in Patients Treated with Drug-Eluting Stenting after Rotational Atherectomy for Complex Calcified Coronary Lesions.

Authors:  Bin Hu; Changbo Xiao; Zhijian Wang; Dean Jia; Shiwei Yang; Shuo Jia; Guangyao Zhai; Hongya Han; Xiaohan Xu; Dongmei Shi; Yujie Zhou
Journal:  J Clin Med       Date:  2022-07-19       Impact factor: 4.964

4.  Staged percutaneous angioplasty of a long calcified left anterior descending artery with rotablation in a patient with stable angina.

Authors:  Jakub Podolec; Piotr Szolc; Monika Durak; Wojciech Zajdel; Łukasz Niewiara; Krzysztof Żmudka
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-06-19       Impact factor: 1.426

5.  Reappraisal Value of a Modified Rotational Atherectomy Technique in Contemporary Coronary Angioplasty Era.

Authors:  Haojian Dong; Daisuke Hachinohe; Zhiqiang Nie; Yoshifumi Kashima; Jianfang Luo; Takuya Haraguchi; Hidemasa Shitan; Tomohiko Watanabe; Yutaka Tadano; Umihiko Kaneko; Takuro Sugie; Ken Kobayashi; Daitaro Kanno; Morio Enomoto; Katsuhiko Sato; Tsutomu Fujita
Journal:  J Interv Cardiol       Date:  2020-01-23       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.